ReviR Therapeutics Marks Significant Clinical Milestone in Rare Disease Treatments and Expands Operations in China ReviR Therapeutics announces the first dosing in its Phase 1 study and gains CDE clearance for orphan drug indications in China, forging new paths for US expansion.

ReviR Therapeutics Marks Significant Clinical Milestone in Rare Disease Treatments and Expands Operations in China #United_States #San_Francisco #ReviR_Therapeutics #Orphan_Drug #RTX-117

ReviR Therapeutics Gains FDA Orphan Drug Designation for RTX-117 as a Treatment for Charcot-Marie-Tooth Disease ReviR Therapeutics has received FDA Orphan Drug Designation for RTX-117, aimed at treating Charcot-Marie-Tooth Disease and addressing critical medical needs.

ReviR Therapeutics Gains FDA Orphan Drug Designation for RTX-117 as a Treatment for Charcot-Marie-Tooth Disease #United_States #ReviR_Therapeutics #Brisbane #CMT_disease #RTX-117

ReviR Therapeutics and Kennedy's Disease Association Team Up for Groundbreaking Research in Neuromuscular Disorders ReviR Therapeutics partners with the Kennedy's Disease Association to advance treatment for spinal and bulbar muscular atrophy, providing hope for those affected by this rare condition.

ReviR Therapeutics and Kennedy's Disease Association Team Up for Groundbreaking Research in Neuromuscular Disorders #United_States #ReviR_Therapeutics #Kennedy's_Disease_Association #neuromuscular_disorder #Brisbane,_California